Kaleem S Atchia1, Christopher J D Wallis2, Neil Fleshner2, Paul Toren1. 1. Department of Surgery, Faculty of Medicine, Université Laval, Quebec City; Centre Hospitalier Universitaire (CHU) de Québec Research Centre, Oncology Division, Quebec City, QC, Canada. 2. Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Abstract
INTRODUCTION: We sought to address whether there are clinical responses when patients who are failing gonadotropin-releasing hormone (GnRH) agonist therapy are switched to degarelix. Androgen-deprivation therapy remains the backbone of treatment for disseminated prostate cancer and may be achieved with orchiectomy, GnRH agonists, or degarelix, a GnRH antagonist. METHODS: We conducted a systematic review and meta-analysis with a search of the BIOSIS Previews, Embase, International Pharmaceutical Abstracts, MEDLINE, and Google Scholar databases using key terms. Quantitative meta-analysis was performed to provide a pooled estimate of prostate specific antigen (PSA) response at three months. RESULTS: Thirteen studies were identified, eight of which were included in the qualitative and quantitative analyses. Patient characteristics were broadly similar between the studies. Out of 155 patients across all included studies, 20 had stable PSA after the switch (12.9%), 14 had a 10-30% decrease in PSA (9.0%), three had a 30-50% decrease (1.9%), and 13 had a more than 50% decrease (8.4%). Random effects meta-analysis of these data demonstrated a pooled response rate of 27.75% (95% confidence interval 18.9-36.5%; I2=7.9%). Changes in testosterone levels following the switch could not be quantitatively assessed due to lack of sufficient data. CONCLUSIONS: Our results suggest that a switch to GnRH antagonist following progression on a GnRH agonist may result in a stable or decreased PSA at three months in about 30% of patients. This information should be considered among the potential options to discuss with patients with a rising PSA on GnRH agonist therapy.
INTRODUCTION: We sought to address whether there are clinical responses when patients who are failing gonadotropin-releasing hormone (GnRH) agonist therapy are switched to degarelix. Androgen-deprivation therapy remains the backbone of treatment for disseminated prostate cancer and may be achieved with orchiectomy, GnRH agonists, or degarelix, a GnRH antagonist. METHODS: We conducted a systematic review and meta-analysis with a search of the BIOSIS Previews, Embase, International Pharmaceutical Abstracts, MEDLINE, and Google Scholar databases using key terms. Quantitative meta-analysis was performed to provide a pooled estimate of prostate specific antigen (PSA) response at three months. RESULTS: Thirteen studies were identified, eight of which were included in the qualitative and quantitative analyses. Patient characteristics were broadly similar between the studies. Out of 155 patients across all included studies, 20 had stable PSA after the switch (12.9%), 14 had a 10-30% decrease in PSA (9.0%), three had a 30-50% decrease (1.9%), and 13 had a more than 50% decrease (8.4%). Random effects meta-analysis of these data demonstrated a pooled response rate of 27.75% (95% confidence interval 18.9-36.5%; I2=7.9%). Changes in testosterone levels following the switch could not be quantitatively assessed due to lack of sufficient data. CONCLUSIONS: Our results suggest that a switch to GnRH antagonist following progression on a GnRH agonist may result in a stable or decreased PSA at three months in about 30% of patients. This information should be considered among the potential options to discuss with patients with a rising PSA on GnRH agonist therapy.
Authors: Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small Journal: N Engl J Med Date: 2018-02-08 Impact factor: 91.245
Authors: Alexandra Masson-Lecomte; Laurent Guy; Philippe Pedron; Franck Bruyere; Morgan Rouprêt; Bonaventure Nsabimbona; Mickael Dahan; Patrice Hoffman; Laurent Salomon; Dimitri Vordos; Andras Hoznek; Philippe Le Corvoisier; Pierrick Morel; Claude Abbou; Alexandre de la Taille Journal: World J Urol Date: 2012-04-15 Impact factor: 4.226
Authors: L Klotz; D Drachenberg; R Singal; A Aprikian; Y Fradet; M Kebabdjian; M Zarenda; J Chin Journal: Prostate Cancer Prostatic Dis Date: 2014-09-02 Impact factor: 5.554
Authors: Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder Journal: BJU Int Date: 2008-12 Impact factor: 5.588
Authors: Edouard G Mills; Lisa Yang; Morten F Nielsen; Moustapha Kassem; Waljit S Dhillo; Alexander N Comninos Journal: Endocr Rev Date: 2021-11-16 Impact factor: 19.871